KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Raw Materials (2017 - 2020)

Amneal Pharmaceuticals has reported Raw Materials over the past 4 years, most recently at $162.7 million for Q1 2020.

  • For Q1 2020, Raw Materials changed N/A year-over-year to $162.7 million; the TTM value through Mar 2020 reached $162.7 million, changed N/A, while the annual FY2019 figure was $172.2 million, 5.23% down from the prior year.
  • Raw Materials for Q1 2020 was $162.7 million at Amneal Pharmaceuticals, down from $172.2 million in the prior quarter.
  • Over five years, Raw Materials peaked at $205.1 million in Q3 2018 and troughed at $140.1 million in Q4 2017.
  • A 4-year average of $178.4 million and a median of $180.9 million in 2018 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: increased 29.71% in 2018 and later decreased 11.13% in 2019.
  • Year by year, Raw Materials stood at $140.1 million in 2017, then increased by 29.71% to $181.7 million in 2018, then fell by 5.23% to $172.2 million in 2019, then decreased by 5.48% to $162.7 million in 2020.
  • Business Quant data shows Raw Materials for AMRX at $162.7 million in Q1 2020, $172.2 million in Q4 2019, and $182.8 million in Q3 2019.